Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine, GSK2282512A, (FLU Q-QIV) When Administered in Children

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 2282512A (Primary) ; Hepatitis A vaccine inactivated
Indications Hepatitis A; Influenza A virus infections; Influenza B virus infections
Focus Registrational; Therapeutic Use
Sponsors GlaxoSmithKline Biologicals; GSK

Most Recent Events

11 Dec 2013 Results published in the New England Journal of Medicine.
27 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
27 Jan 2012 Actual patient number 5220 added as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight